IAS 2017: Novel Long-Acting Drug Shows Promise for HIV Treatment and PrEP

A single oral dose of MK-8591, a long-acting antiretroviral in a novel drug class, suppressed HIV for 7 days in an early clinical trial, and the drug also appears to protect monkeys from rectal infection with an HIV-like virus, researchers reported at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.


IAS 2017: Demonstration Projects Explore Feasibility of PrEP for Adolescents in South Africa

One of the first studies to explore the acceptability, safety, and use of pre-exposure prophylaxis (PrEP) in adolescents in an African context has found that PrEP was safe and tolerable, although PrEP usage and adherence did tail off during the 12 months of the program.


IAS 2017: WHO Recommends Urgent Care Package for People with Advanced HIV Disease

A new package of measures to ensure rapid initiation of antiretroviral treatment and diagnosis of opportunistic infections has been recommended by the World Health Organization (WHO) to reduce the still high rates of death among people diagnosed with HIV at a very advanced stage of disease.


IAS 2017: First Protease Inhibitor Combo Pill Maintains Viral Suppression

The first once-daily single-tablet regimen containing a protease inhibitor maintained viral suppression in almost everyone who switched after achieving undetectable HIV RNA on a multi-pill regimen, according to a report at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.


IAS 2017: Improved Cryptococcal Meningitis Treatment Could Save Thousands of Lives

Urgent action is needed to improve access to the antifungal drug flucytosine, say investigators, following the presentation of the results of a trial showing that treatment containing flucytosine is superior to any other form of therapy in reducing the risk of death from cryptococcal meningitis in people with very advanced HIV disease.


IAS 2017: Another HIV Vaccine Efficacy Trial Will Start This Year

A year ago, one of the biggest pieces of prevention news at the Durban International AIDS Conference was the announcement that a large HIV vaccine efficacy study would start in South Africa. HVTN 702, now running, is only the eighth human vaccine efficacy trial ever run in the history of the HIV epidemic, and the first since 2009.


Coverage of the 2017 IAS Conference on HIV Science coverage of the 9th International AIDS Society Conference on HIV Science, July 23-26, 2017, in Paris.

Full coverage listing by topic

IAS 2017 website